Condition
T2DM
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 30 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
30 shownA Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes MellitusNCT07599410 · 2026-07-14
RECRUITINGA Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease.NCT07496177 · 2026-07-09
RECRUITINGStudy to Evaluate HM15275 in Subjects With Type 2 Diabetes MellitusNCT07527650 · 2026-05-18
RECRUITINGA Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes MellitusNCT07347080 · 2026-01-20
RECRUITINGCofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.NCT07019012 · 2025-07-30
RECRUITINGEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and MetforminNCT07093476 · 2025-07-18
RECRUITINGEffects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 DiabetesNCT06942195 · 2025-05-22
RECRUITINGThe Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic NephropathyNCT06843304 · 2024-01-01
RECRUITINGComparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM PatientsNCT03987308 · 2019-07-02
RECRUITINGPREDICT-DM: Community Pharmacy-Based Point-of-Care Testing for Undiagnosed T2DMNCT07795918 · 2026-10-01
NOT_YET_RECRUITINGIntegrated Diabetes and Oral Health Care in OmanNCT07809477 · 2026-09-01
NOT_YET_RECRUITINGEndocrine Disruption, Menopause, and Poor Sleep in wOmen With Type 2 Diabetes: Effects on Cardiovascular HealthNCT07486986 · 2026-09-01
NOT_YET_RECRUITINGThe Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLDNCT07289750 · 2026-05-01
NOT_YET_RECRUITINGPilot of Continuous Glucose Monitor-Augmented Food Is MedicineNCT07148713 · 2025-09-19
ACTIVE_NOT_RECRUITINGThe Effect of Semaglutide on Bone HealthNCT07165158 · 2025-09-15
NOT_YET_RECRUITINGFitbit and AI Chatbot in Sedentary Primary Care Patients With T2DNCT07005362 · 2025-09-03
COMPLETEDDetecting Type 2 Diabetes From VoiceNCT07421921 · 2025-09-01
COMPLETEDA Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 DiabetesNCT07139548 · 2025-08-31
NOT_YET_RECRUITINGA Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneNCT07139535 · 2025-08-31
NOT_YET_RECRUITINGEmbecta AID System in Adults With Type 2 DiabetesNCT06692153 · 2025-01-01
WITHDRAWNEfficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With MetforminNCT06571591 · 2024-08-27
COMPLETEDA Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 DiabetesNCT05996380 · 2023-06-09
UNKNOWNA Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMNCT05680129 · 2023-01-10
COMPLETEDA Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM PatientsNCT05680155 · 2022-12-29
COMPLETEDHydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 DiabetesNCT06797115 · 2022-07-18
COMPLETEDEfficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 DiabetesNCT03563794 · 2018-06-10
UNKNOWNThe Imaging Genetic Study of Type 2 Diabetes and DepressionNCT03564431 · 2017-12-01
UNKNOWNEfficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and MetforminNCT01990469 · 2014-01-01
COMPLETEDMetabolic Surgery for Metabolic SyndromeNCT07183137 · 2010-09-01
COMPLETEDSleep Disordered Breathing and Impaired Glucose Homeostasis in Obese ChildrenNCT02037100 · 2007-06-01
UNKNOWNCommon interventions
MetforminDRUG3PlaceboDRUG3EmpagliflozinDRUG2RAY1225DRUG24 years of clinical evaluations.OTHER1actoplus metDRUG1AlogliptinDRUG1alogliptin and actoplus metDRUG1An AID System.DEVICE1BeinaglutideDRUG1Ca-1000OTHER1Ca-500OTHER1CGM-Augmented FIMBEHAVIORAL1ControlOTHER1CSII(insulin Lispro)DRUG1CSII+VildagliptinDRUG1CT-L03 Group 1DRUG1CT-L03 Group 2DRUG1DulaglutideDRUG1EcnoglutideDRUG1Ecnoglutide high dosageDRUG1Ecnoglutide low dosageDRUG1Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））DRUG1FIM onlyBEHAVIORAL1Fitbit and AI ChatbotBEHAVIORAL1
Leading sponsors
Celltrion
2
Guangdong Raynovent Biotech Co., Ltd
2
Hangzhou Sciwind Biosciences Co., Ltd.
2
The First Affiliated Hospital of Xiamen University
2
Beijing Hospital
1
Chinese PLA General Hospital
1
Embecta Corp.
1
Fujian Shengdi Pharmaceutical Co., Ltd.
1
Hanmi Pharmaceutical Company Limited
1
Huazhong University of Science and Technology
1
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
1
Jiangsu HengRui Medicine Co., Ltd.
1
Kunming Medical University
1
LG Life Sciences
1
Oman Ministry of Health
1
Trial status mix
RECRUITING9
COMPLETED8
NOT_YET_RECRUITING7
UNKNOWN4
ACTIVE_NOT_RECRUITING1
WITHDRAWN1
Phase mix
PHASE37
NA5
PHASE44
PHASE23
EARLY_PHASE11
PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.